Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice

Panelists discuss how recent advances in treating Lower-Risk Myelodysplastic Syndromes have impacted clinical practice, using hypothetical scenarios to demonstrate their approach to incorporating new data into patient care.

EP. 11: Imetelstat and IMerge Trial Review

November 4th 2024

Panelists discuss how imetelstat, a telomerase inhibitor recently approved by the FDA on June 6, 2024, works and its efficacy as demonstrated in the IMerge trial, while highlighting key adverse events that community oncologists should be vigilant about when considering this treatment for patients with lower-risk MDS.

EP. 12: Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

November 4th 2024

Panelists discuss how the treatment landscape for lower-risk MDS may evolve with emerging novel agents and combination strategies, including studies on luspatercept vs epoetin alfa, luspatercept combinations, elritercept, roxadustat, and canakinumab, potentially offering new options for patients with suboptimal responses to current therapies.

EP. 13: The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

November 11th 2024

Panelists discuss how community oncologists can apply key takeaways from this clinical scenario in their practice, emphasizing the importance of collaborating with academic clinicians for optimal patient identification and treatment selection in the evolving landscape of lower-risk MDS management.